All In Biotech

Drug Trial Radar · NCT00696800

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,509 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,509

Actual

Start

Jun 27, 2006

Primary completion

Nov 19, 2007

Study completion Jan 15, 2008

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jun 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 36 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy and safety of a single injection of 150 μg Corifollitropin Alfa (Organon 36286) to induce multifollicular development for controlled ovarian stimulation using daily recombinant FSH (recFSH) as a reference. The primary hypothesis is that a single injection of Corifollitropin Alfa is non-inferior to daily treatment with recFSH in initiating multifollicular growth.

Conditions

  • In Vitro Fertilization

Interventions

  • Corifollitropin alfaDrug

    On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.

  • RecFSH / Follitropin beta (Days 1 to 7)Biological

    Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

  • Placebo Corifollitropin alfaDrug

    Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.

  • Placebo RecFSH / follitropin betaDrug

    Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

  • RecFSH / Follitropin beta (Days 8 to hCG)Biological

    From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

  • GanirelixDrug

    On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

  • hCGBiological

    When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

  • ProgesteroneBiological

    On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate)Time frame: Assessed at least 10 weeks after embryo transfer (up to 1 year)
  2. Mean Number of Oocytes RetrievedTime frame: Up to 36 hours after administration of hCG (up to 1 year)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.